For research and educational purposes only. Not intended for human consumption.
SHLP-2
Limited Research- •CXCR7 receptor activation pathway characterized
- •Diet-induced obesity protection studies (2024)
- •Hypothalamic appetite regulation research
Small Humanin-Like Peptide 2 | Metabolic Regulation
Overview
What is SHLP-2?
SHLP-2 (Small Humanin-Like Peptide 2) is a mitochondria-derived peptide that provides metabolic benefits by protecting against diet-induced obesity, improving insulin sensitivity, suppressing food intake, enhancing energy expenditure, and regulating lipid metabolism in preclinical studies. It activates the CXCR7 receptor to mediate its metabolic effects.
Key Benefits
Anti-obesity effects, improved insulin sensitivity, appetite suppression, enhanced energy expenditure, lipid metabolism regulation.
Mechanism of Action
Binds to and activates chemokine receptor 7 (CXCR7). Suppresses food intake, reduces hypothalamic expression of orexigenic neuropeptides (AgRP and NPY), increases energy expenditure via enhanced thermogenesis, and activates POMC neurons in the hypothalamic arcuate nucleus.
Molecular Information
Pharmacokinetics
Research Indications
Anti-Obesity Effects
Prevents high-fat diet-induced body weight gain, reduces fat mass, and decreases hepatic steatosis in mouse models.
Appetite Suppression
Suppresses food intake for up to 8 hours post-refeeding by reducing orexigenic neuropeptide expression.
Energy Expenditure
Increases energy expenditure via enhanced thermogenesis.
Research Protocols
Disclaimer: No human clinical dosing established. All research is preclinical using mouse models. Human trials are lacking.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Mouse Anti-Obesity Study | 2 mg/kg | IP administration | Intraperitoneal |
| Central Administration (Research) | ICV dosing | As per study design | Intracerebroventricular |
Timing: No established timing. Mouse studies show effects lasting up to 8 hours post-administration.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature
Add appropriate sterile water or BAC water
Gently swirl to dissolve
Solution should be clear
Store refrigerated at 2-8°C
Use per research protocol guidelines
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Preclinical Research Only
No human clinical trials. All data from mouse models and in vitro studies.
Strong Preclinical Evidence
Multiple studies showing metabolic benefits in diet-induced obesity models.
Identified Receptor Target
CXCR7 receptor identified as mechanism of action.
Age-Related Decline
Circulating levels decrease with aging, suggesting therapeutic potential.
Limited Availability
Research-grade compound with limited commercial availability.
What to Expect
- •No human timeline established
- •Mouse studies show rapid appetite suppression effects (up to 8 hours)
- •Anti-obesity effects observed over multi-week treatment periods
- •Improved insulin sensitivity and lipid profiles in preclinical models
- •Effects may vary between species
Side Effects & Safety
Side Effects
- •Limited safety data - preclinical research only
- •No serious adverse events reported in mouse studies
- •Endogenous peptide family with expected physiological safety profile
- •Monitor for any unexpected effects
- •Not approved for human use
When to Stop
- •Any unexpected adverse effects
- •Signs of metabolic disturbance
- •As directed by research protocol
- •Consult healthcare provider
References
3 StudiesAnti-Obesity Effects in HFD Mice (2023)
Mouse | 2 mg/kg IP | Multiple weeks | Prevented weight gain and hepatic steatosis
SHLP2 administration prevented HFD-induced body weight gain, reduced fat mass, lowered leptin levels, and decreased hepatic steatosis in mice.
View StudyCXCR7 Receptor Identification (2023)
High-throughput screening | In vitro | CXCR7 identified as receptor
SHLP2 binds to and activates chemokine receptor 7 (CXCR7), mediating its metabolic effects.
Ceramide Metabolism Study (2025)
Mouse | Various | Lipidomics | Lowers ceramides and sphingolipids
SHLP2 lowers plasma levels of ceramides, glycosylated ceramides, sphingolipids, and diacylglycerols.
Quick Start Guide
Research Disclaimer
SHLP-2 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving SHLP-2 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of SHLP-2 for any purpose. Consult qualified professionals for any research applications.